<?xml version='1.0' encoding='utf-8'?>
<document id="30117017"><sentence text="Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor."><entity charOffset="25-33" id="DDI-PubMed.30117017.s1.e0" text="Ixazomib" /></sentence><sentence text="Ixazomib, the first oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy"><entity charOffset="0-8" id="DDI-PubMed.30117017.s2.e0" text="Ixazomib" /><entity charOffset="79-91" id="DDI-PubMed.30117017.s2.e1" text="lenalidomide" /><entity charOffset="96-109" id="DDI-PubMed.30117017.s2.e2" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.30117017.s2.e0" e2="DDI-PubMed.30117017.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30117017.s2.e0" e2="DDI-PubMed.30117017.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30117017.s2.e0" e2="DDI-PubMed.30117017.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30117017.s2.e1" e2="DDI-PubMed.30117017.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30117017.s2.e1" e2="DDI-PubMed.30117017.s2.e2" /></sentence><sentence text=" Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome, and preferentially binds to and inhibits the β5 chymotrypsin-like proteolytic site"><entity charOffset="1-9" id="DDI-PubMed.30117017.s3.e0" text="Ixazomib" /></sentence><sentence text=" Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose"><entity charOffset="1-9" id="DDI-PubMed.30117017.s4.e0" text="Ixazomib" /></sentence><sentence text=" Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9"><entity charOffset="1-9" id="DDI-PubMed.30117017.s5.e0" text="Ixazomib" /></sentence><sentence text="5 days) with first-order linear absorption (oral bioavailability of 58%)" /><sentence text=" Plasma exposures of ixazomib increase in a dose-proportional manner"><entity charOffset="21-29" id="DDI-PubMed.30117017.s7.e0" text="ixazomib" /></sentence><sentence text=" A high-fat meal decreases both the rate and extent of ixazomib absorption, supporting administration on an empty stomach"><entity charOffset="55-63" id="DDI-PubMed.30117017.s8.e0" text="ixazomib" /></sentence><sentence text=" Population PK analyses demonstrated that no dose adjustment is required based on age, body size/weight, race, sex, mild-to-moderate renal impairment, or mild hepatic impairment" /><sentence text=" Results from dedicated studies indicate that a reduced starting dose (from 4 to 3 mg) is appropriate for patients with severe renal impairment, end-stage renal disease requiring dialysis, or moderate-to-severe hepatic impairment" /><sentence text=" Non-cytochrome P450 (CYP)-mediated metabolism appears to be the major clearance mechanism for ixazomib"><entity charOffset="95-103" id="DDI-PubMed.30117017.s11.e0" text="ixazomib" /></sentence><sentence text=" Drug-drug interaction studies have shown no meaningful effects of strong inhibitors of CYP3A on ixazomib PK; however, the strong inducer rifampin caused a clinically relevant reduction in ixazomib exposure, supporting the recommendation to avoid concomitant administration of ixazomib with strong CYP3A inducers"><entity charOffset="189-197" id="DDI-PubMed.30117017.s12.e0" text="ixazomib" /><entity charOffset="277-285" id="DDI-PubMed.30117017.s12.e1" text="ixazomib" /><pair ddi="false" e1="DDI-PubMed.30117017.s12.e0" e2="DDI-PubMed.30117017.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30117017.s12.e0" e2="DDI-PubMed.30117017.s12.e1" /></sentence><sentence text=" Exposure-response analyses of data from the phase III TOURMALINE-MM1 registrational study demonstrate a favorable benefit-risk profile for the approved dose and regimen of weekly ixazomib 4 mg on days 1, 8, and 15 of each 28-day cycle"><entity charOffset="180-188" id="DDI-PubMed.30117017.s13.e0" text="ixazomib" /></sentence><sentence text="" /></document>